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Aims Elevation of intracellular Na in the failing myocardium contributes to contractile dysfunction, the negative force–fre-
quency relationship, and arrhythmias. Although phospholemman (PLM) is recognized to form the link between signalling
pathways and Na/K pump activity, the possibility that defects in its regulation contribute to elevation of intracellular Na
has not been investigated. Our aim was to test the hypothesis that the prevention of PLM phosphorylation in a PLM3SA
knock-in mouse (in which PLM has been rendered unphosphorylatable) will exacerbate cardiac hypertrophy and cellular
Na overload. Testing this hypothesis should determine whether changes in PLM phosphorylation are simply bystander
effects or are causally involved in disease progression.
Methods
and results
In wild-type (WT) mice, aortic constriction resulted in hypophosphorylation of PLM with no change in Na/K pump
expression. This under-phosphorylation of PLM occurred at 3 days post-banding and was associated with a progressive
decline in Na/K pump current and elevation of [Na]i. Echocardiography, morphometry, and pressure-volume (PV) catheter-
ization confirmed remodelling, dilation, and contractile dysfunction, respectively. In PLM3SA mice, expression of Na/K ATPase
was increased and PLM decreased such that net Na/K pump current under quiescent conditions was unchanged (cf. WT myo-
cytes); [Na+]i was increased and forward-mode Na/Ca exchanger was reduced in paced PLM
3SA myocytes. Cardiac hyper-
trophy and Na/K pump inhibition were significantly exacerbated in banded PLM3SA mice compared with banded WT.
Conclusions Decreased phosphorylation of PLM reduces Na/K pump activity and exacerbates Na overload, contractile dysfunction,
and adverse remodelling following aortic constriction in mice. This suggests a novel therapeutic target for the treatment
of heart failure.
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1. Introduction
In the heart, the Na/K ATPase is crucial for the maintenance of the
normal transmembrane Na gradient. A reduction of this gradient has
been implicated in a variety of pathologies including ischaemia/reperfu-
sion,1,2 hypertrophy, and heart failure (HF).3 –5 In hypertrophy and HF,
many aspects of excitation–contraction (E–C) coupling are clearly
altered; however, the elevation in intracellular Na may contribute to
(i) the negative force–frequency relationship (FFR), (ii) slowed relax-
ation, (iii) arrhythmias, and (iv) impaired mitochondrial energetics.6,7
While a component of the elevation of intracellular Na may reflect an
increase in Na influx,8 there is a large body of evidence showing that
Na/K pump function may also be compromised.3– 5,9 Specifically, in
cardiac hypertrophy, we (and others—see Pogwizd et al.3 and Verdonck
et al.5 for reviews) have shown that Na/K pump function is reduced.
It is now well established that FXYD proteins are tissue-specific regula-
tors of Na/K ATPase activity. In the heart, FXYD1, or phospholemman
(PLM), has now been extensively characterized and has been shown to
be an essential mediator of Na/K pump activation in response to cellular
signalling cascades [specifically protein kinase A (PKA) and protein kinase
C (PKC)]. Unphosphorylated PLM exerts a tonic inhibition on the pump
which is relieved by PLM phosphorylation of one, or all of three, residues
on its cytoplasmic tail [serines (Ser) Ser63, Ser68,orSer/Thr69].Thisphos-
phorylation is hence important for the dynamic control of intracellular Na
during increases inheart rateandpreventionofNaoverloadduring ‘fightor
flight’.10–12 In addition to PLM, a range of other ion regulation or E–C
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coupling proteins, such as L-type Ca channels, phospholamban (PLB), the
ryanodine receptor (RyR), and troponin I, are all phosphorylated by the
activation of PKA, PKC, or NO-dependent pathways. Although acute
inotropic activation of these pathways helps increase the Ca transient
while maintaining efficient relaxation, chronic activation may lead to Ca
overload, diastolic dysfunction, and arrhythmias.13,14
It isnowwidelyacceptedthatsympatheticactivation isanacuteandmain-
tained response to cardiac overload and is a critical component of the pro-
gression intoHF. In theminutes andhours followingamyocardial infarction,
for example, this immediate sympathetic outflow may be necessary to
maintain cardiac output, blood pressure, and peripheral perfusion.
However, the sustained long-term activation of the sympathetic nervous
system is now recognized as one of the detrimental aspects of the progres-
sion towards HF and as such b-blockade is the first-line therapy. The
SOLVD studies show that even in asymptomatic patients, plasma cate-
cholamines are elevated.15 The up-regulation of sympathetic outflow is
assumed to be an immediate response to myocardial stress and as such it
seems reasonable to hypothesize that, in the minutes, hours, and days fol-
lowing acute stress, PKA substrates will by hyperphosphorylated. Although
it has been reported that the hyperphosphorylation of the sarcoplasmic
reticulum (SR) Ca-release channel RyR2 persists, the majority of studies
suggest that, after a poorly described initial peak, the phosphorylation of
PLB declines to below baseline as the b-adrenoceptor signalling pathway
down-regulates.16–18
Despite the importance of PLM in the regulation of intracellular Na,
and the considerable evidence suggesting intracellular Na is elevated
in hypertrophied and failing myocardium and contributes to diastolic
dysfunction, the role of PLM and its phosphorylation in the overloaded
and failing heart has not been systematically characterized. Bossuyt
et al.19 have reported hyperphosphorylation of PLM in a rabbit model
of volume overload-induced dilated failure, whereas El-Armouche
et al.20 have reported hypophosphorylation of PLM in failing human
hearts—attributable to down-regulation of inhibitor-1 and increased
protein phosphatase 1 (PP-1) activity. This lack of consensus may reflect
different models or different stages of the disease process. It is also
evident that simply reporting up- or down-regulation of PLM phosphor-
ylation doesnotdistinguish between aneffect that causally influences the
progression of the disease and one that is simply a bystander—reporting
dynamic disease-induced changes in PKA and PKC signalling pathways.
The primary aim of this study was therefore to test the hypothesis
that the specific prevention of PLM phosphorylation in a PLM knock-in
mouse (in whichPLMhasbeen renderedunphosphorylatable)will exacer-
bate cardiac hypertrophyand cellular Na overload. Testing this hypothesis
shoulddeterminewhetheranychanges inPLMphosphorylationare simply
bystander effects or are causally involved in the progression of the disease.
To do this, we have generated a knock-in mouse (PLM3SA) in which the
PLM residues phosphorylated by PKC and PKA10 (Ser63, 68, and 69)
have been mutated to alanines. To meet this principle aim, we have initially
characterized changes in PLM expression and phosphorylation, and func-
tional indices of hypertrophy, Na pump function and intracellular Na, in
genetically normal C57BL/6J mice subjected to suprarenal aortic constric-
tion. We have then established the baseline characteristics of the PLM3SA
mouse heart and determined response to aortic constriction of the
PLM3SA mice and their wild-type (WT) littermates.
2. Methods
Full details of the Methods used in this study are given in Supplementary
material online.
2.1 Animals and PLM3SA mice
All experiments were performed in accordance with the Guidance on the
Operation of Animals (Scientific Procedures) Act, 1986 (UK), the Directive
of theEuropeanParliament (2010/63/EU), and receivedapproval by the local
ethics review board. Male WT mice (C57BL/6J) or male PLM3SA knock-in
mice, or their WT littermates, were used. PLM3SA mice express an unpho-
sphorylatable form of PLM in which Ser63, 68, and 69 have all been
mutated to alanines (see Supplementary material online for more detail).
This mutated PLM gene is expressed under the control of the endogenous
FXYD-1 promoter, resulting in normally regulated levels of PLM globally
expressed in tissues thatusually expressPLM(i.e. heart, smooth muscle, skel-
etal muscle etc.). Initial hypertrophy studies (in which sham and banded
animals were compared) were conducted in C57/Bl6 mice (Harlan UK,
Ltd). Heterozygote breeders were used to generate homozygote PLM3SA
mice and they were compared with WT littermates.
2.2 Hypertrophy model
Myocardial hypertrophy was induced by pressure overload following supra-
renal aortic constriction (banding) in 6-week-old C57BL/6J mice (20–22 g),
PLM3SA knock-in mice, or their WT littermates.21 The reproducibility of the
aortic constriction, and hence pressure overload, was assessed by post-
mortem measurement of the residual luminal area (RLA) and constrictions
falling outside predefined limits were excluded (see Supplementary material
online).
For all surgical procedures and echocardiography, mice were anaesthe-
tized by inhalation of isoflurane/O2 mixture (2/98%). Adequacy of anaesthe-
sia was controlled by monitoring corneal reflex and respiration (rate, depth,
and pattern of breathing). Acute postoperative analgesia was a single bupre-
norphine (Vetergesic 0.3 mg/mL solution) injected i.p. at dose 20 mg/kg.
Euthanasia [after invasive pressure–volume (PV) measurements] was per-
formed by overdose of isoflurane. Death was confirmed by monitoring
cardiac activity and respiration. Heart excision (for myocyte isolation or
in vitro assessment of cardiac function) was performed after terminal anaes-
thesia by i.p. injection of pentobarbital (Pentoject 200 mg/mL solution) at
dose 300 mg/kg and heparin (150 U).
2.3 Assessment of cardiac function
Cardiac function was measured in vivo in anaesthetized mice 5 and 9 weeks
after surgery in sham and banded animals. Cardiac dimensions and contract-
ility were measured using 2D echocardiography (Visualsonics Vevo 770
ultrasound system with a 30 MHz linear signal transducer) and left ventricu-
lar (LV) PV measurements using an admittance catheter (ADVantage, Sci-
sence, Canada). In vitro assessment of cardiac function was made in
Langendorff-perfused hearts excised from mice at 5 and 9 weeks after
sham or banding surgery and FFRs constructed over the range of 400–
750 bpm.
2.4 Electrophysiological measurements of Na/K
pump activity
Myocytes were isolated from hearts of sham and banded mice (from 5 to 9
weeks post-surgery) using conventional collagenase digestion techniques
and Na/K pump current measured using whole-cell voltage clamp, as
described previously.22 Cell capacitance wasmeasured from the capacitance
transient generated on application of a voltage step from the holding poten-
tial of290 to280 mV. Currents generated were recorded via an Axopatch
200A amplifier and a pClamp10 software (Molecular Devices, CA, USA).
2.5 Fluorescencemeasurements of intracellular
Na and Ca
Intracellular Na was measured in quiescent and paced myocytes using 1,3-
benzenedicarboxylic acid, 4,4′-[1,4,10-trioxa-7,13-diazacyclopentadecane-
7,13-diylbis(5-methoxy-6,12-benzofurandiyl)]bis-, tetrakis[(acetyloxy)methyl]
ester (SBFI) as previously described by Despa et al.23 (see Supplementary
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material online for details). Intracellular Ca and Na/Ca exchanger (NCX)
activity were measured in paced myocytes using Fura-2 AM as described
in Supplementary material online.
2.6 Immunoblotting
Hearts were harvested from banded and sham-operated animals 4 and 8
weeks after aortic banding surgery. Tissue was prepared, and western
blots run, as described in Supplementary material online.
2.7 Statistical data analysis
Quantitative data are shown as means+ standard error of the mean (SEM).
Differences between experimental groups were tested by one-way or
two-way ANOVA followed by a Bonferroni post hoc test or by paired or un-
paired t-tests as appropriate. P-values of,0.05 were considered significant.
Western blots that were quantitatively compared with multiple control and
test samples were all run on the same resolving gel. The average densitomet-
ric value for the multiple control samples was defined as 1.0 and all individual
bands (including the control samples) were normalized to this average—
hence providing an SEM for control and test samples. In electrophysiological
and fluorescence experiments, a number of cells from each isolation were
studied; observations from a single-cell isolation were averaged and the
n-value represents the number of hearts from which cells were isolated.
3. Results
3.1 Pressure overload-induced progressive
cardiac remodelling and contractile
dysfunction in C57BL/6J mice
The progression and characteristics of cardiac hypertrophy were con-
firmed in this model (see Supplementary material online, Figure S1 and
Table S1). A progressive cardiac remodelling was observed over the
8-week period such that LV mass/tibia length ratio increasing from
5.4+0.18 (n ¼ 8) in sham to 12.3+0.65 (n ¼ 8) in banded animals.
This increase in LV mass was accompanied by decreases in ejection frac-
tion, cardiac output, and velocity time integral (see Supplementary ma-
terial online, Figure S1). Detailed analysis of echocardiographic data from
sham and banded animals 4 and 8 weeks after surgery is shown in Sup-
plementary material online, Table S1. Accompanying the increase in LV
mass was a progressive systolic and diastolic dilation and contractile
dysfunction.
3.2 LV hypertrophy did not change PLM/
NKA ratio, but reduced PLM
phosphorylation at Ser63 and 68
Western blot analyses were carried out on whole LV homogenates
to determine changes in the expression of PLM, Na/K ATPase (a1 and
a2 subunits), and PLM phosphorylation in response to aortic con-
striction. Pressure overload did not change a1 and a2 Na/K ATPase
or PLM expression. Importantly, therefore, in this model, the PLM:a1
ratio was unaffected by hypertrophy (Figure 1). However, PLM phos-
phorylation at Ser63 and 68 was significantly reduced in banded
mice (Figure 1). PLM phosphorylation at Ser69 was unaffected by pres-
sure overload (mean data not shown). Hypophosphorylation of PLM
could be expected to reduce Na/K pump function in the hypertrophied
myocardium.
To test the hypothesis that this hypophosphorylation of PLM is pre-
ceded by a transient period of hyperphosphorylation (before sympathetic
pathways down-regulate), we studied two further cohorts of mice banded
for 3 and 14 days. Figure 2A andB shows that as early as 3 days there was no
detectable increase in PLM phosphorylation. In fact, PLM Ser68 phosphor-
ylationwasalreadydecreasedby3and14dayspost-banding,and therewas
a similar non-significant trend for an early decrease in Ser63 phosphoryl-
ation. The scatter in these data is large, possibly due to the varying and un-
controllable sympathetic stress associated with the recent surgery in both
the sham and banded animals. Figure 2A and B shows NCX and SERCA2a
expression at these early time-points. NCX was markedly up-regulated by
3 days, whereas SERCA2a clearly starts to decrease by Day 3 and is signifi-
cantly down by Day 14.
3.3 NKA current density decreased in
response to pressure overload
To investigate functional consequences of PLM hypophosphorylation,
we measured Na/K pump current in ventricular myocytes isolated
from banded and sham-operated mice. Cell capacitance was signifi-
cantly increased by 67% in banded mice (Figure 3A). This compares
with a 128% increase in heart weight/tibia length ratio, indicating that
the increase in heart mass reflects not only the increase in myocyte
size but also increases in non-myocyte components. Interestingly, as
exemplified in Figure 3B, the absolute amount of pump current was
greater in hypertrophied compared with sham-operated cells but,
when normalized for cell size, pump current density was markedly
reduced in hypertrophied cells (Figure 3C). There was a strong correl-
ation between the level of hypertrophy and the extent of pump current
inhibition (Figure 3D). Interestingly, this relationship, although shifted
to higher pump current densities, is also seen within cells from sham-
treated animals. That is, within the usual distribution of normal cell
sizes isolated from control hearts, larger cells have lower pump cur-
rent densities. The relationship between cell size and pump current
density appears to be curvilinear and is steeper in control than hypertro-
phied cells (Figure 3D).
3.4 Contractile function in Langendorff
hearts isolated from sham and banded mice
At a constant pacing rate of 550 bpm, hypertrophied hearts showed sig-
nificantly reduced contractile function over 20 min of control perfusion
(Figure 3E). The FFR for sham and banded hearts is shown in Figure 3F. In
sham-operated hearts, this relationship was initially positive over the
range 400–500 bpm before LV developed pressure (LVDP) declined
at higher heart rates. In banded hearts, the FFR was entirely negative
over the range of 400–750 bpm.
3.5 The basal cardiac phenotype of PLM3SA
mice
In this study, we have used the PLM3SA mouse to examine the role of
PLM phosphorylation in cardiac hypertrophy. Before banding these
animals,however,wehaveundertakenacharacterizationof thebasalpheno-
type. Supplementary material online, Table S2 shows echocardiographic
and PV catheter-based assessment of basal function in anaesthetized
PLM3SA mice and their WT littermates. Under basal conditions, there
werenosignificant changes in themajorityof contractile andothervariables.
3.6 Na/K ATPase and PLM expression
in hearts from PLM3SA andWTmice
Figure 4 shows the expression of Na/K ATPase a subunits, PLM, and
other ion translocating proteins in hearts from 14- to 16-week-old
WT and PLM3SA mice. In hearts from PLM3SA mice, a1 subunit expres-
sion, although elevated, was not significantly increased while PLM
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expression was significantly decreased. This combination of slightly
increased a1 and decreased PLM resulted in a significant decrease in
the PLM/a1 ratio (Figure 4C). Figure 4B also confirms that antibodies to
PLM phosphorylated at Ser63, 68, and 69 were unable to detect phos-
phorylated PLM in PLM3SA mice.
The Na/K ATPase a2 subunit expression was increased in PLM3SA
hearts (Figure 4D). This, combined with the decrease in PLM expres-
sion, results in a significant decrease in PLM/a2 ratio. Under basal con-
ditions, this increase in the relative expression of both a1 and a2
relative to PLM may reflect an adaptive response to the inhibitory
effect of unphosphorylated PLM on Na/K transport. This adaptation
appears not to be confined to the Na/K pump complex, but significantly
higher levels NCX were also measured in PLM3SA hearts (SERCA2a
levels were unaffected) (Figure 4E). While such adaptive changes may
allow normal ion regulation under basal unstimulated conditions, the
mutation of PLMs phosphorylation sites should render the Na/K
pump unresponsive to PKA activation or b-receptor stimulation.
In vivo where tonic autonomic control may be important, this may
explain the normal contractility seen in vivo despite significant difference
in vitro.
3.7 Basal Na/K pump current in PLM3SA
mice and response to forskolin
We have previously shown that basal Na/K pump current was similar
in both genotypes, but while WT myocytes responded to forskolin
(50 mmol/L), PLM3SA myocytes were unresponsive.24 Under unstimu-
lated conditions, PLM in WT myocytes is up to 40% phosphorylated.10
This basal phosphorylation is obviously absent in PLM3SA mice. It there-
foreappears that, in unstimulatedPLM3SA myocytes, the inhibitoryeffect
of expressing unphosphorylatable PLM is offset by the compensatory
decrease in PLM expression and increase in alpha subunit expression
(Figure 4). Baseline pump current is therefore maintained at normal
levels, but is subsequently unable to increase when exposed to forskolin
or indeed any other kinase-mediated stimulus.
3.8 Aortic constriction and global and
cellular remodelling in PLM3SA mice
If the hypophosphorylation of PLM is not causally involved in the pro-
gression of hypertrophy, and simply ‘reports’ on the down-regulation
of b-adrenergic signalling pathways, then PLM3SA and WT littermates
Figure 1 Protein expression and phosphorylation changes measured 8 weeks after aortic banding in C57BL/6J mice. Representative western blots (A)
and quantitative changes in PLM/NKA a1 ratio and PLM phosphorylation (B). PLM phosphorylation was normalized to total PLM. (C) Changes in the ex-
pression of NCX and SERCA2a in sham and banded hearts. PLM, phospholemman; NKAa1, Na/K ATPasea1 subunit; CSQ, calsequestrin; NCX, sodium–
calcium exchanger; SERCA2a, sarco/endoplasmic reticulum Ca ATPase type 2a. In A, the top and bottom panels show images of the same samples cropped
from different gels. All other panels were each run on a single gel and images cropped within a gel (CSQ or total PLM was used as loading controls). Data inB
and C are mean+ SEM, *P, 0.05; n ¼ 6–11 (sham) and n ¼ 6–10 (banded).
Phospholemman and cardiac hypertrophy development 75
should be equally vulnerable to hypertrophy. On the contrary, if PLM
hypophosphorylation is causally involved in the progression of hyper-
trophy, then remodelling following aortic constriction may be expected
to be more severe in the PLM3SA mouse (where PLM phosphorylation is
not just limited it is completely prevented).
Figure 5 shows that the hypertrophic response to pressure overload
was markedly increased in PLM3SA mice compared with WT animals.
In WT mice 8 weeks after surgery, left ventricle/body weight (LV/Bw)
ratio increased by 56% from 4.1+ 0.06 mg/g in shams to 6.4+
0.65 mg/g in banded animals. In PLM3SA mice, however, this hypertrophic
response was substantially exacerbated with LV/Bw ratio, increasing by
142% from 3.8+0.12 to 9.2+1.08 mg/g. This markedly increased
remodelling was accompanied by significantly more dilation both in
systole and in diastole and an exacerbation of the banding-induced fall
in ejection fraction. More detailed analysis of the echocardiographic
measurements is shown in Supplementary material online, Table S3.
All ejection-phase indices were significantly lower in PLM3SA mice
after aortic constriction.
LV function was also assessed by a catheter-based PV analysis ap-
proach in closed-chest mice (see Supplementary material online, Table
S3). No differences were observed in sham-treated groups, but
banded mice showed demonstrable LV dysfunction. After aortic con-
striction, end-systolic pressure was elevated to the same extent in
WT and PLM3SA mice, suggesting that both genotypes were subjected
to the same level of pressure overload in response to aortic banding.
This was confirmed by post-mortem observation of the RLA which
was identical in banded mice of both genotypes (data not shown). Any
differences between WT and PLM3SA mice were, therefore, not attrib-
utable to changes in the severity of the pressure overload. Interestingly,
the major difference between PLM3SA banded and WT banded mice was
a more profound slowing of relaxation (dP/dtmin) and the LV relaxation
time-constant (TWeiss). These data are consistent with the echocardio-
graphic measurements and indicate a substantial degree of systolic and
diastolic dysfunction in PLM3SA mice after aortic constriction.
3.9 Na/K pump current and intracellular Na
in hypertrophied PLM3SA myocytes
To investigate the relevance of PLM-dependent regulation of Na/K pump
activity in cardiac remodelling,we measured Na/K pump current and intra-
cellular Na in myocytes from banded and sham-operated mice of both
genotypes. In addition, Na/K pump and PLM expression was measured
in LV homogenates from WT and PLM3SA hearts. Pressure overload did
not significantly change a1 and a2 Na/K ATPase or PLM expression and
PLM to Na/K ATPase a1 subunits (NKA; a1 and a2 subunits) ratios in
WT and PLM3SA mice (see Supplementary material online, Figure S2).
Consistent with the profoundly increased cardiac remodelling in the
PLM3SA mice, the hypertrophy-induced increase in cell size was
Figure 2 Protein expression and phosphorylation changes measured 3 and 14 days after aortic banding in C57BL/6J mice. Representative western
blots (A) and quantitative changes (B) in PLM phosphorylation (Ser63 and 68); NCX and SERCA2a expression in sham and banded hearts, respectively.
In A, each row represents images cropped from different gels probed with different antibodies as shown. Data are mean+ SEM, *P, 0.05; n ¼ 6
(sham and banded).
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significantly greater in myocytes frombandedPLM3SAvs. bandedWTmice
(Figure 6A). The hypertrophy-induced reduction in Na/K pump current
density was also more than doubled from a 24% reduction in banded
WT myocytes to a 57% reduction in banded PLM3SA myocytes
(Figure 6B). The relationship between Na/K pump current density and
cell size is shown inFigure6C. Aspreviouslyshown(Figure3D), this relation-
ship is shifted to the right and is shallower in banded myocytes. In PLM3SA
myocytes, the further reduction in pump current density was seen across
all cell sizes and is again shallow and right-shifted vs. shams. Figure 6E shows
intracellular Na measured in quiescent myocytes from sham and banded
PLM3SA mice and their WT littermates. In unpaced cells, intracellular Na
was not significantly higher in PLM3SA vs. WT shams, but was significantly
elevated in both genotypes in response to banding. While this elevation in
intracellularNa inPLM3SAmyocyteswasnotsignificantlyhigher thanthat in
WTmyocytes, it is important tonote that thesemeasurementsweremade
in quiescent cells. Indeed, in the presence of field stimulation (1 Hz), we
observed a significant increase in intracellular Na in PLM3SA myocytes
compared with WT (Figure 7A).
3.10 NCX in PLM3SA myocytes
The elevation of intracellular Na in PLM3SA myocytes will influence the
activity of NCX. In addition, PLM has been shown to directly interact
with NCX itself with phosphorylated PLM inhibiting exchanger
activity.25,26 We therefore investigated NCX activity in paced myocytes
isolated from WT and PLM3SA mice. Figure 7A shows that pacing signifi-
cantly elevated intracellular Na in both WT and PLM3SA cells (cf.
Figure 6E). The rate of decline in the Ca transient induced by the rapid
and maintained application of caffeine was used as an index of forward-
mode NCX activity in both genotypes (Figure 7B andC ). Figure 7D shows
that the rate constant of Ca recovery was significantly prolonged in
PLM3SA myocytes, consistent with the elevation of intracellular Na
shown in Figure 7A. Application of caffeine in the presence of Na-free
Tyrode prevents forward-mode NCX and induces reverse-mode
NCX increasing intracellular Ca (Figure 7B).
4. Discussion
The principle finding of this study is that decreased phosphorylation of the
Na/K ATPase regulatory protein PLM reduces Na/K pump activity and
exacerbates Na overload, contractile dysfunction, and adverse remodel-
ling following aortic constriction in mice. The direct contribution of this
Na overload to contractile (particularly diastolic) dysfunction and remod-
elling suggests a novel therapeutic target for the treatment of HF.
In C57BL/6J WT mice, cardiac PLM is hypophosphorylated in re-
sponse to aortic constriction. This is associated with a reduction in
Na/K pump function, as assessed by voltage-clamping, and an increase
Figure 3 Na/K pump current measurements in myocytes and cardiac function in Langendorf hearts isolated from sham and banded C57BL/6J mice. (A)
Cell capacitance showing significant myocyte hypertrophy in the banded group, (B) original traces showing example Na/K pump current recordings (the
downward deflections represent periods of K-free superfusion), (C) mean pump current density in cells isolated from sham and banded hearts normalized
to cell capacitance, and (D) relationship between pump current density and cell size (capacitance). The exponential decay curvewas fitted to all points using
the equationY ¼ (Y02 Plateau) × exp(2K × X) + Plateau,whereK is the ‘rate’ constant. (E) LVDP overa 20 min period of aerobicperfusion (pacing rate
550 bpm). (F ) LV pressure–frequency relationship in sham and banded hearts. [Numerical data are mean+ SEM, A and C, 23 cells from eight sham mice
(n ¼ 8) and 27 cells from nine banded mice (n ¼ 9). InE and F, comparison between groups (sham and banded, n ¼ 6/group) was performed using two-way
ANOVA, repeated measures, *P, 0.05].
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in intracellular Na. The hypophosphorylation of PLM was mirrored by
a similar hypophosphorylation of another PKA substrate PLB (not
shown). Although the contribution of PLB hypophosphorylation has
been extensively studied, the relationship between PLM and the Na/K
ATPase in hypertrophy and failure remains relatively poorly defined.
As has previously been extensively reported, we find that SERCA2a
expression is down-regulated and NCX significantly up-regulated in
the hypertrophied heart. PLM and Na/K ATPase expression, however,
remained essentially unchanged such that the ratio of PLM/Na/K
ATPase alpha1 subunit was constant over the 8-week period of
cardiac remodelling.
These observations are consistent with our studies in human HF
samples, where PLM was similarly hypophosphorylated.20 In this
study, hypophosphorylation was attributed to a down-regulation of
inhibitor-1 and increased PP-1 phosphatase activity. Although we
hypothesized that this hypophosphorylation may be preceded by a
period of hyperphosphorylation (prior to b-adrenoceptor pathway
down-regulation), no evidence was found for this at two earlier time-
points 3 or 14 days after banding. Since the cardiac dysfunction
induced byacute sympathetic activation, such as in Takotsubocardiomy-
opathy, resolves within days or weeks,27 it is possible that b-adrenergic
signalling down-regulation occurs early after banding despite chronic
elevation of circulating catecholamines. Soltysinska et al.28 have
reported chronic down-regulation of b-signalling after 16 days of iso-
proterenol infusion, but did not look at earlier time-points. We
attempted to investigate time-points earlier than 3 days post-banding
(not shown), but the stress of the surgery in both banded and sham
animals was so profound and variable that the data were too variable
to be useful. These data therefore suggest that if there is a transient
peak in sympathetically mediated phosphorylation of PKA substrates
early after aortic constriction, it occurs within 3 days and this signalling
pathway rapidly down-regulates leading to a maintained hypophosphor-
ylation of PLM and PLB.
In this model, in WT mice, expression of Na/K ATPasea1 subunit and
PLM was unchanged and hence the decrease in Na/K pump current mea-
sured in isolated cells we attribute to the dephosphorylation of PLM.
This decrease in Na/K pump current was curvilinearly associated with
the extent of myocyte hypertrophy (the larger the cell the smaller the
pump current density) and with an increase in intracellular Na. In
these studies, total pump current was measured in voltage-clamped
myocytes in a ruptured-patch mode where the subsarcolemmal Na con-
centrationmay not exactly matchpipette Na. Pipette Na in these experi-
ments was fixed at 25 mmol/L to allow the detection of changes in pump
Vmax and Km for Na. However, in hypertrophied cells, diffusional access
Figure 4 Basal protein expression and PLM phosphorylation measured in hearts from WT and PLM3SA mice. Representative western blots for Na/K
pump a subunits, NCX and SERCA 2a proteins (A) and PLM phosphorylation (B). Quantitative changes in protein expression (C–E). Alpha1/2, Na/K
ATPase a1/2 subunits; PLM, phospholemman; SERCA2a, sarco/endoplasmic reticulum Ca ATPase type 2a; NCX, sodium–calcium exchanger. WT and
PLM3SA samples were run on the same gels. In A and B, each pair of rows represents images cropped from different gels probed with different antibodies
as shown. CSQ was used as a loading control. Data are mean+ SEM, *P, 0.05; n ¼ 10–12 (WT and PLM3SA).
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to the subsarcolemmal space may be more limited than in control cells
and it is possible that the decline in pump current in the larger more
hypertrophied cells could also reflect changes in subsarcolemmal Na
due to limitations in cell dialysis.
In the introduction to this paper, we raise the possibility that the hypo-
phosphorylation of PLM in the hypertrophied heart, as confirmed in this
study, may simply be a bystander effect—reporting on the prevailing
state of the b-adrenergic signalling pathway without causally affecting
the progression of the disease. In this study, we have used the PLM3SA
mouse to address this issue. Since PLM in this mouse is rendered unpho-
sphorylatable, development of the disease should be unaffected if it is
simply a reporter and exacerbated if it is causally involved. Data pre-
sented here clearly indicate that the complete prevention of PLM phos-
phorylation at Ser63, 68, and 69 markedly exacerbates remodelling.
Hearts from PLM3SA respond to the same pressure overload as WT
hearts with a markedly more severe hypertrophy, increased contractile
dysfunction, and more depressed Na/K pump function. This demon-
strates that the extent of PLM phosphorylation influences the develop-
ment of the disease and is not simply passively reporting on the state of
PKA or PKC activation.
In addition to the mutations in PLM, the PLM3SA mice also have adap-
tive changes in NCX that could influence both E–C coupling and the
response to a hypertrophic stimulus. The overexpression of NCX
seen in these mice is, however, unlikely to exacerbate cardiac hyper-
trophy. Adachi-Akahane et al.29 showed that mice overexpressing
NCX show no evidence of cardiac hypertrophy. So, it seems unlikely
that the increased vulnerability of the PLM3SA heart to hypertrophic re-
modelling and contractile dysfunction is attributable to these relatively
small adaptive changes in NCX.
In addition to changes in baseline NCX expression, PLM3SA myocytes
also showa significant increase in the expression of thea2 isoform of the
Na/K ATPase. Correll et al.30 have suggested that the a2 isoform is ‘less
regulated by PLM’ and provides a mechanism by whicha2 can efficiently
couple to NCX, particularly in pathology, to maintain ion (and particu-
larly Ca) regulation. In their study, they show that the ‘forced’ overex-
pression of a2 leads to a reduction in PLM and PLM phosphorylation.
It seems possible that the reciprocal is true in our study—that is, the
‘forced’ expression of unphosphorylated PLM leads to increaseda2 ex-
pression. This compensatory change may allow Na regulation in micro-
domains relevant to E–C coupling to be preserved despite a bulk rise in
cytoplasmic Na. In normal (unbanded) hearts, this increase in a2 is sig-
nificant with PLM3SA hearts having more a2 protein and a lower PLM/
a2 ratio (Figure 4). In banded PLM3SA hearts, this relationship seems to
persist but, with the increased variability introduced by hypertrophy, fi-
brosis, etc., statistical significance is lost (see Supplementary material
online, Figure S2).
PLM, in addition to interacting with Na/K ATPase, has also been
shown to directly modulate NCX independent of changes in ion gradi-
ents.25 It is therefore possible that the pro-hypertrophic effects of the
PLM3SA mutation could be attributable to a direct interaction
between the mutated PLM and NCX. Studies from Cheung et al.26
have shown that phosphorylated PLM inhibits NCX. As WT PLM is sub-
stantially phosphorylated at baseline (Figure 4B), it is possible that the
3SA mutant would effectively stimulate NCX when compared with
WT controls. However, this was not seen. In the present study, we
found that NCX activity was significantly reduced in PLM3SA myocytes
compared with the WT cells (Figure 7), despite a significant increase in
NCX expression in the PLM3SA hearts (Figure 4). This is consistent
with the study of Song et al.31 who reported that unphosphorylated
PLM (four potential phosphorylation sites mutated to alanines in a
3S1T mutant) transfected into rat myocytes was without effect on con-
traction and presumably also without effect on NCX. The reduction in
forward-mode NCX activity inPLM3SA myocytes is thereforemost likely
to be due to the increased [Na]i observed in 3SA cells and not to a direct
Figure 5 Cardiac function and morphometry assessed by echocardiography in sham and banded WT and PLM3SA mice. (A) Representative echocardio-
graphic images (M-mode) 8 weeks after aorta constriction. (B) Quantitative measures of cardiac function and hypertrophy in sham and banded hearts.
LV/Bw is left ventricular weight as a function of body weight. Data are mean+ SEM, P, 0.05; n ¼ 10 (sham, WT), n ¼ 9 (banded, WT), n ¼ 6
(sham, PLM3SA), n ¼ 7 (banded, PLM3SA). Comparison was performed using two-way ANOVA (*P, 0.05).
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interaction between the mutated PLM and NCX. This increase in Na
may also explain the negative FFR seen in Langendorff-perfused hearts
from banded animals as this has also previously been associated with
an elevation of intracellular Na in normal rodent hearts32 and hypertro-
phied/failing human hearts.7
The observation that the hypophosphorylation of PLM, and asso-
ciated Na/K pump inhibition, exacerbates cardiac remodelling and dys-
function raises the possibility that conversely, the preservation of PLM
phosphorylation and/or Na/K pump stimulation may be therapeutically
useful in HF. In the context of HF, superficially, there appears to be an
interesting historical contradiction in this hypothesis. Na/K pump inhib-
ition, in the form of digitalis, has been used to treat HF for over 200 years.
Digitalis, however, appears to provide symptomatic relief rather than a
positive effect on long-term prognosis. In the largest trial of its kind,
the Digitalis Investigation Group (DIG) showed digoxin-reduced hospi-
talization due to worsening HF symptoms, but had no long-term effect
on mortality.33 Conversely, there is a remarkable correlation between
the ability of wide variety of agents to stimulate the Na/K pump and a
beneficial outcome of many clinical trials for HF.34 ACE inhibitors,
ARBs, aldosterone antagonists, NO donors, and insulin are all known
to stimulate the Na/K ATPase and, in clinical trials, these agents have
all been shown to be protective.34 The exception to this is b-blockers
(which might be expected to limit pump stimulation), but these are
clearly beneficial. Incongruously, it is, however, now generally accepted
that b-blockers can somehow preserve cellular adrenergic signalling
perhaps by preventing b-receptor down-regulation.16 Thus, the weight
of evidence suggests that a selective means of increasing Na/K pump
activity that can increase Na extrusion without inducing PKA activation
and Ca overload is required. Such a therapy may complement existing
therapies such as b-blockade. Limiting Na overload by selective pump
stimulation may also be beneficial in diseases other than HF such as
hypertension, angina, and arrhythmias (especially catecholaminergic
polymorphic ventricular tachycardia) where Na overload is known to
be causally involved.35
Figure 6 Na/K pump current and intracellular Na measurements in myocytes isolated from sham and banded WT and PLM3SA hearts. (A) Cell capaci-
tance showing significantly increased myocyte hypertrophy in the PLM3SA banded group, (B) mean pump current density in cells isolated from sham and
banded WT and PLM3SA hearts normalized to cell capacitance, and (C ) relationship between pump current density and cell size (capacitance). Each indi-
vidual dataset is fitted with a linear regression. (D) Example trace showing calibration of SBFI fluorescence, and (E) mean intracellular Na concentrations in
sham and banded myocytes from WT and PLM3SA mice. Data in A, B, and E are mean+ SEM; in A and B, seven cells from four sham WT (n ¼ 4), nine cells
from five banded WT (n ¼ 5), four cells from four sham PLM3SA (n ¼ 4), and 10 cells from five banded PLM3SA hearts (n ¼ 5); in E, 15 cells from five sham
WT (n ¼ 5), 12 cells from seven banded WT (n ¼ 7), 24 cells from seven sham PLM3SA (n ¼ 7), and 27 cells from five banded PLM3SA hearts (n ¼ 5).
Comparison was performed using two-way ANOVA (*P, 0.05).
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